drugset
Drugs / Bimiralisib
last change Jun 2025 re-read 2 minutes ago

Bimiralisib

also known as PQR309 · NC-B5 · PI3K-IN-2

Small molecule

Developed for
cancer · primary central nervous system lymphoma · actinic keratosis · breast cancer · glioblastoma · head and neck squamous cell carcinoma · lymphoma · non-Hodgkin lymphoma
Investigated by
PIQUR Therapeutics AG · Churchill Hospital · M.D. Anderson Cancer Center · University College London Hospitals · University Hospital, Basel, Switzerland · University Hospital, Zürich
+24 more · Barts Cancer Institute · Case Western Reserve University · Catalan Institute of Oncology · Charite University, Berlin, Germany · Clinical Center Kragujevac · Clinical Center Nis, Nis · Fundación Instituto Valenciano de Oncología · Hospital Clinic of Barcelona · Hospital Universitari Vall d'Hebron Research Institute · Hospital Universitario Ramon y Cajal · Insel Gruppe AG, University Hospital Bern · Institut Curie · Institute for Oncology and Radiology Serbia, Belgrade · Mayo Clinic · Roswell Park Cancer Institute · Royal Marsden NHS Foundation Trust · TORQUR · University Clinical Center, Sarajevo · University Clinical Centre of Republic of Srpska · University Hospital Freiburg · University Hospital Munich · University of Haifa · University of Stuttgart · Weill Medical College of Cornell University

Trials 10 · a red edge is where a trial was stopped

today NCT06319794 · Ph 2 NCT02483858 · Ph 1 NCT03740100 · Ph 2 NCT03120000 · Ph 2 NCT03127020 · Ph 2 NCT02723877 · Ph 1/2 NCT02669511 · Ph 2 NCT02850744 · Ph 2 NCT02249429 · Ph 2 NCT01940133 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02483858 Mar 2019 cancer PIQUR Therapeutics AG Completed No outcome recorded
Phase 1 NCT01940133 Jan 2014 → Mar 2015 cancer PIQUR Therapeutics AG Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02723877 Mar 2016 → Oct 2018 breast cancer PIQUR Therapeutics AG Completed No outcome recorded
Phase 27 trials
Phase 2 NCT06319794 Apr 2024 → Jun 2025 actinic keratosis TORQUR Completed No outcome recorded
Phase 2 NCT03740100 Jan 2019 → Aug 2020 head and neck squamous cell carcinoma M.D. Anderson Cancer Center Terminated No outcome recorded
Phase 2 NCT03120000 Dec 2017 → Dec 2018 primary central nervous system lymphoma PIQUR Therapeutics AG Withdrawn No outcome recorded
Phase 2 NCT03127020 Jun 2016 → Mar 2019 non-Hodgkin lymphoma PIQUR Therapeutics AG Completed No outcome recorded
Phase 2 NCT02669511 Nov 2015 → Jan 2018 primary central nervous system lymphoma PIQUR Therapeutics AG Completed No outcome recorded
Phase 2 NCT02850744 Jul 2015 → Nov 2017 glioblastoma PIQUR Therapeutics AG Terminated No outcome recorded
Phase 2 NCT02249429 May 2015 → Sep 2018 lymphoma PIQUR Therapeutics AG Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as bimiralisib ClinicalTrials.gov intervention name — accepted as the source's own label NCT02249429 ↗
2

NCT03740100 ↗

NCT06319794 ↗
Known as NC-B5 ChEMBL registry synonym — accepted as the source's own label CHEMBL4084907 ↗
Known as PI3K-IN-2 ChEMBL registry synonym — accepted as the source's own label CHEMBL4084907 ↗
Known as PQR309 “bimiralisib (PQR309)” NCT02249429 ↗
7

NCT02483858 ↗

NCT01940133 ↗

NCT02850744 ↗

NCT03127020 ↗

NCT03120000 ↗

NCT02723877 ↗

NCT02669511 ↗
Action Inhibit “dual PI3K and mTORC1/2 inhibitor PQR309” PMID 29660598 ↗ Apr 2018
Modality Small molecule — CHEMBL4084907 ↗
Route Oral “Dosing will be orally, once a day for the duration of the trial.” NCT01940133 ↗